ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO728

Cystatin C and Cystatin C-Based GFR Markers for Prediction of Mortality in Elderly Patients with CKD

Session Information

  • Geriatric Nephrology
    October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Geriatric Nephrology

  • 1100 Geriatric Nephrology

Authors

  • Bevc, Sebastjan, University Clinical Centre Maribor, Maribor, Slovenia
  • Hojs, Nina, University Clinical Centre Maribor, Maribor, Slovenia
  • Knehtl, Masa, University Clinical Centre Maribor, Maribor, Slovenia
  • Piko, Nejc, University Clinical Centre Maribor, Maribor, Slovenia
  • Ekart, Robert, University Clinical Centre Maribor, Maribor, Slovenia
  • Hojs, Radovan, University Clinical Centre Maribor, Maribor, Slovenia
Background

The prevalence of chronic kidney disease (CKD) in the elderly is high. Serum cystatin C is an accurate marker of kidney function and also has prognostic utility in CKD patients. The aim of our study was to determine the prediction of cystatin C and cystatin-C based markers of kidney function (eGFR) on long-term survival in elderly CKD patients.

Methods

In our study 58 adult Caucasian patients, older than 65 years (50% women; mean age 73 years; range from 65 to 85 years), were included. Patients with known malignancy, thyroid disease and/or on steroid therapy were not enrolled in the study. In each patient 51CrEDTA clearance, serum cystatin C (immunonephelometric method) and eGFR using two cystatin C-based formulas (CKD-EPI cystatin and FAS cystatin) were determined on the same day and patients were then followed for 12 years or until their death.

Results

The mean values: 51CrEDTA clearance 53.3±17.4 ml/min/1.73m2, serum cystatin C 1.79±0.5 mg/l, CKD-EPI cystatin 36.1±13.6 ml/min/1.73m2, FAS cystatin 40.1±11.7 ml/min/1.73m2. In the follow up period of 12 years 48 (83%; 24 women and 24 men) of our elderly CKD patients died. Cox regression analysis showed different hazard ratios (HR) for death: for 51CrEDTA clearance HR was 1.024 (95% CI 1.001-1.042; P=0.009), for serum cystatin C HR was 2.021 (95% CI 1.264-3.229; P=0.003), for CKD-EPI cystatin HR was 1.034 (95% CI 1.008-1.062; P=0.01), for FAS cystatin HR was 1.041 (95% CI 1.010-1.071; P=0.008).

Conclusion

Our results show that in elderly CKD patients the highest hazard ratio for all-cause mortality has serum cystatin C compared to the cystatin C-based markers of kidney function (eGFR).